ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1755

The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus

John D. Mountz1, Jun Li2, Jennie Hamilton3, PingAr Yang4, Qi Wu5, Bao Luo6, Yanna Ding3, Hao Li6, David Crossman7, Erik Malarkey8, Yong Zhou2, Yang-Xin Fu9 and Hui-Chen Hsu5, 1Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, 2Medicine, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 6Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Genetics, University of Alabama at Birmingham, Birmingham, AL, 8Cell, Development, and Integrated Biology, University of Alabama at Birmingham, Birmingham, AL, 9Department of Pathology, The University of Chicago, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus, Macrophage and apoptotic clearance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Animal Models Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  
Marginal zone macrophages (MZMs) of the spleen are essential for rapid and
tolerogenic clearance of apoptotic cells (ACs).  MZMs are decreased in two
mouse models of lupus and in SLE subject spleens.  Absence of lymphotoxin beta
receptor (LTβR) signaling in the MZMs in lupus BXD2 mice leads to a defect
in megakaryoblastic leukemia 1 (MKL1)/actin polymerization.  The purpose of this
study was to determine the mechanism underlying the development of inflammatory
AC phagocytic MZMs. 

Methods:   Stimulation of LTβR
signaling was carried out in vitro with an agonistic anti-LTβR and blocked
in vivo with a soluble LTβR-Fc.  MZMs were analyzed and sorted by flow
cytometry.  Gene expression analysis was carried out by RT-PCR.  Time-lapse
imaging was carried out on a Nikon A1R two-photon microscope.  ACs were induced
by dexamethasone and labeled with DAPI.  Actin polymerization was determined
using a GFP LifeAct adenovirus transfection of macrophages (Mɸs).

Results:   Two-photon live
cell imaging revealed defects in actin polymerization and slower cytoplasmic
encapsulation of ACs at the surface of Mɸ from BXD2 and B6-Mkl1‒⁄‒
mice.  Ingestion of ACs occurred after prolonged membrane interaction (>5
min) with ACs.  In contrast, stimulation of BXD2 Mɸ with an agonistic
anti-LTβR resulted in strong actin polymerization.  These Mɸs exhibited
robust proactive degradation of ACs characterized by cytoplasm/actin
protrusions, phagocytic cup formation, and digestion of ACs. In vivo LTβR
signaling blockade of MZMs after administration of LTβR-Fc resulted in an
increase in Il6 and a decrease in Il10.  There was also a 4-6
fold increase in the expression of serine proteases, normally found in azurophilic
granules, including neutrophil elastase (Elane), Protenase-3, and Cathepsin
G, in MZMs of BXD2 compared to B6 mice.  Increases in ELANE activity were
observed in BXD2 MZMs following AC phagocytosis or after addition of RNPs but
were suppressed by anti-LTβR. 
Gene analysis shows that there was down-regulation of the intracellular
inhibitor of TLR signaling, TRIM30α, in MZMs of BXD2, B6-Mkl1‒⁄‒
or LTβf/fxCD19.Cre
mice, compared to that in B6 MZMs. Down-regulation of TRIM30α in MZMs of BXD2
and B6-Mkl1‒⁄‒
was further verified by confocal imaging analysis.

Conclusion:   The results
show that decreased LTβR signaling in MZMs results in enhanced immunogenic
response to ACs via: (1) a defect in actin polymerization and defective AC
phagolysosomes formation; (2) a decreased repression of serine proteases that
can bind to DNA or RNA protein complexes in the endolysosome to promote
inflammatory degradation of ACs that can stimulate TLRs; and (3) a decrease in
TRIM30α which is a key inhibitor of downstream TLR signaling from
endolysosomes and Mɸ.  Since MZMs are essential for tolerogenic uptake of
ACs, the work here pinpoints specific cellular mechanistic and molecular
defects and suggest novel interventions that may reverse the immunogenic uptake
of ACs.

 

 

 


Disclosure: J. D. Mountz, None; J. Li, None; J. Hamilton, None; P. Yang, None; Q. Wu, None; B. Luo, None; Y. Ding, None; H. Li, None; D. Crossman, None; E. Malarkey, None; Y. Zhou, None; Y. X. Fu, None; H. C. Hsu, None.

To cite this abstract in AMA style:

Mountz JD, Li J, Hamilton J, Yang P, Wu Q, Luo B, Ding Y, Li H, Crossman D, Malarkey E, Zhou Y, Fu YX, Hsu HC. The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-lymphotoxinmegakaryoblastic-leukemia-1actin-axis-as-a-master-regulator-of-tlr-signaling-in-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-lymphotoxinmegakaryoblastic-leukemia-1actin-axis-as-a-master-regulator-of-tlr-signaling-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology